脂必泰联合小剂量阿托伐他汀治疗颈动脉粥样硬化的疗效观察及对外周血hs-CRP和Treg细胞的影响

Efficacy of Zhibitai capsules combined with low-dose atorvastatin in the treatment of cervical arteriosclerosis and its effects on high-sensitivity C-reactive protein and regulatory T cells in the peripheral blood

目的观察脂必泰联合小剂量阿托伐他汀治疗颈动脉粥样硬化的效果及对患者血浆超敏C反应蛋白(hs-CRP)水平和调节性T淋巴细胞(Treg细胞)的影响。方法回顾性选取山西省汾阳医院2021年1月至2022年4月住院及门诊收治的颈动脉粥样硬化患者104例为研究对象,按照治疗方法不同分为对照组52例,观察组52例。对照组给予阿托伐他汀钙片20 mg每天1次口服治疗,观察组给予阿托伐他汀钙片10 mg每天1次口服,同时联合脂必泰胶囊0.24 g早晚各1粒口服治疗。治疗8周后,评估两组患者总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平以及外周血hs-CRP水平和Treg细胞比例的变化。结果治疗后,观察组患者HDL-C为(1.53±0.29)mmol/L,Treg细胞比例为(5.52±1.38)%,均高于对照组的(1.19±0.21)mmol/L、(4.48±0.86)%,差异均有统计学意义(t=6.84、4.61,均P<0.05)。观察组TC、TG、LDL-C、hs-CRP水平分别为(2.88±0.27)mmol/L、(1.21±0.15)mmol/L、(2.01±0.19)mmol/L、(2.58±0.43)mg/L,均低于对照组的(3.68±0.41)mmol/L、(1.33±0.19)mmol/L、(2.69±0.31)mmol/L、(3.70±0.25)mg/L,差异均有统计学意义(t=11.75、3.57、12.31、17.23,均P<0.05)。两组患者治疗前颈动脉斑块差异无统计学意义,治疗后斑块缩小,观察组疗效优于对照组(P<0.05)。结论在颈动脉粥样硬化患者治疗中,小剂量阿托伐他汀钙片联合脂必泰胶囊口服,安全有效,不良反应少,同时能降低血清hs-CRP水平,提升外周血Treg细胞占比,还有助于稳定并缩小斑块。

Objective To investigate the efficacy of Zhibitai capsules combined with low-dose atorvastatin in the treatment of cervical arteriosclerosis and its effects on high-sensitivity C-reactive protein and regulatory T cells in the peripheral blood.Methods A total of 104 patients with carotid arteriosclerosis admitted to Fenyang Hospital from January 2021 to April 2022 were retrospectively included in this study.They were divided into a control group(n=52)and an observation group(n=52)according to different treatment methods.The control group was orally given atorvastatin calcium tablets 20 mg once a day.The observation group was orally given atorvastatin calcium tablets 10 mg once a day,and Zhibitai capsules 0.24 g,one capsule in the morning and one capsule in the evening.After 8 weeks of treatment,changes in total cholesterol,triacylglycerol,high-density lipoprotein cholesterol,low-density lipoprotein cholesterol,high-sensitivity C-reactive protein,and regulatory T cell proportion in the peripheral blood were evaluated.Results After treatment,high-density lipoprotein cholesterol level and regulatory T cell proportion in the observation group were(1.53±0.29)mmol/L and(5.52±1.38)%,respectively,which were significantly higher than(1.19±0.21)mmol/L and(4.48±0.86)%respectively in the control group(t=6.84,4.61,both P<0.05).Total cholesterol,triacylglycerol,low-density lipoprotein cholesterol,and high-sensitivity C-reactive protein levels in the observation group were(2.88±0.27)mmol/L,(1.21±0.15)mmol/L,(2.01±0.19)mmol/L,(2.58±0.43)mg/L,respectively,which were significantly lower than(3.68±0.41)mmol/L,(1.33±0.19)mmol/L,(2.69±0.31)mmol/L,(3.70±0.25)mg/L,respectively in the control group(t=11.75,3.57,12.31,17.23,all P<0.05).There was no significant difference in carotid plaque size pre-treatment between the two groups,but the plaque size decreased after treatment compared with before treatment.The efficacy of Zhibitai capsules combined with low-dose atorvastatin in the treatment of cervical arteriosclerosis in the observation group was superior to that in the control group(P<0.05).Conclusion Oral administration of Zhibitai capsules combined with low-dose atorvastatin for the treatment of cervical arteriosclerosis is safe and has few adverse reactions.The combined therapy can decrease serum high-sensitivity C-reactive protein levels,increase the proportion of regulatory T cells in the peripheral blood,help stabilize plaques,and reduce plaque size.